FOXD3 and glioblastoma: Collectively, our results revealed an important role of FOXD3-AS1 in cell survival and TMZ resistance in GBM cells, which suggests that FOXD3-AS1 may serve as a prognostic biomarker candidate and a potential therapeutic target for GBM treatment.